4/17
07:00 am
btai
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
Medium
Report
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
4/9
07:53 pm
btai
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Medium
Report
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
4/8
07:00 am
btai
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
Medium
Report
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
4/5
01:06 am
btai
Medium
Report
4/2
08:01 am
btai
BioXcel Therapeutics (BTAI) had its price target lowered by HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
Medium
Report
BioXcel Therapeutics (BTAI) had its price target lowered by HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
4/1
07:00 am
btai
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
High
Report
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
4/1
05:53 am
btai
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D [Yahoo! Finance]
High
Report
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D [Yahoo! Finance]
3/29
12:16 pm
btai
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks [Yahoo! Finance]
Medium
Report
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks [Yahoo! Finance]
3/27
07:55 am
btai
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting [Yahoo! Finance]
Medium
Report
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting [Yahoo! Finance]
3/27
07:00 am
btai
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting
Medium
Report
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting
3/23
08:00 am
btai
Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc.
Medium
Report
Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc.
3/17
08:25 am
btai
BioXcel Therapeutics (BTAI) is now covered by Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.
Medium
Report
BioXcel Therapeutics (BTAI) is now covered by Rodman & Renshaw. They set a "buy" rating and a $17.00 price target on the stock.
3/12
02:35 pm
btai
How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs [Yahoo! Finance]
Low
Report
How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs [Yahoo! Finance]
3/11
04:38 pm
btai
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering [Yahoo! Finance]
Low
Report
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering [Yahoo! Finance]
3/11
04:20 pm
btai
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
Low
Report
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
3/11
07:18 am
btai
BioXcel Therapeutics (BTAI) was upgraded by Zacks Research from "strong sell" to "hold".
Low
Report
BioXcel Therapeutics (BTAI) was upgraded by Zacks Research from "strong sell" to "hold".
3/10
02:36 pm
btai
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
Low
Report
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
3/5
11:44 am
btai
BioXcel Therapeutics (BTAI) had its price target lowered by HC Wainwright from $10.00 to $6.00. They now have a "buy" rating on the stock.
Medium
Report
BioXcel Therapeutics (BTAI) had its price target lowered by HC Wainwright from $10.00 to $6.00. They now have a "buy" rating on the stock.
3/5
07:41 am
btai
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal [Yahoo! Finance]
High
Report
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal [Yahoo! Finance]
3/5
07:00 am
btai
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal
High
Report
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal
2/27
06:12 pm
btai
BioXcel Therapeutics, Inc. (BTAI) Discusses Phase III Results and Advances in Treating Acute Agitation in Alzheimer's Dementia Transcript [Seeking Alpha]
Low
Report
BioXcel Therapeutics, Inc. (BTAI) Discusses Phase III Results and Advances in Treating Acute Agitation in Alzheimer's Dementia Transcript [Seeking Alpha]
2/19
07:34 am
btai
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia [Yahoo! Finance]
Medium
Report
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia [Yahoo! Finance]
2/19
07:00 am
btai
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia
Low
Report
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia
2/12
07:00 am
btai
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting
Medium
Report
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting
1/30
07:57 am
btai
BioXcel Therapeutics (NASDAQ:BTAI) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
BioXcel Therapeutics (NASDAQ:BTAI) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.